© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Sticking with the facts, aminophylline didn’t show up on pharmacy shelves overnight. Chemists built on the groundwork of xanthine research from the 1800s, observing how caffeine and theobromine worked across the human body. By the 1930s, asthmatic patients desperate for relief found hope in aminophylline, a compound joining theophylline and ethylenediamine. Doctors began using it for asthma attacks because it hit a sweet spot—reliable bronchodilation and easier formulation compared to earlier theophylline-only preparations. Hospitals kept aminophylline stocked through the mid-20th century, especially for folks wheezing with chronic obstructive pulmonary disease and severe asthma. Massive pharmaceutical effort kept the compound affordable, and medical research kept refining safer dosing, since aminophylline pokes at heart rhythms if you cross certain thresholds.
The story of aminophylline is more than a pill or an injection; it’s a leap in supportive care for asthma and related diseases. People refer to aminophylline as a bronchodilator, but over time, it found purpose in treating apnea of prematurity, acute heart failure, and sometimes emergency medicine, where breathing must be rescued quickly. Unlike some newer agents, aminophylline balances cost with effect, so clinics and hospitals in various parts of the world keep it on formulary. Although inhalers and modern steroids get the spotlight today, aminophylline still delivers results, especially where budgets are tight or allergies limit other options.
Aminophylline presents as a white to pale yellow powder, giving no trouble to identification under standard laboratory lighting. Easily soluble in water, this property helped leaping from tablet form to intravenous solutions, vital for acute care. Chemically, the structure combines theophylline (itself a methylxanthine) with ethylenediamine. That second component keeps aminophylline more water-soluble than the pure methylxanthines—important for rapid IV use. At standard temperatures, the compound remains stable, though it starts decomposing above 64°C, so long shelf life requires simple, cool storage. Identifying it in a lab comes down to straightforward melting point testing and distinctive UV absorption bands.
Every pharmaceutical batch needs robust labeling, and aminophylline draws from strict pharmacopoeias. Strength gets measured by theophylline content, usually labeled as theophylline 80 mg for every 100 mg aminophylline, with ethylenediamine as the remainder. Injections list concentration per milliliter—often 25 mg/ml. Tablets file under strengths between 100 mg and 400 mg, each stamped for batch, expiry, and regulatory numbers. Labels also warn about incompatibility with acidic solutions, reminding clinicians not to mix it carelessly in too many IV combinations, which avoids headaches like precipitation and loss of therapeutic effect.
Manufacturing aminophylline means nothing without precise blending. Chemists start with high-purity theophylline and carefully mix in ethylenediamine under controlled temperatures. Water serves as the main solvent, and technical staff keep pH within a narrow favorable band. Hygroscopic by nature, the finished powder must go right into sealed containers to guard against moisture and clumping. For intravenous preparations, pharmaceutical filtration eliminates microparticulates, and sterilization finishes off the vials without degrading the active compound.
Aminophylline doesn’t boast wild molecular gymnastics, but its reactivity matters. In laboratories, researchers sometimes tweak the structure, attaching various alkyl or aryl groups to the xanthine core to hunt for better bronchodilator profiles or milder side effects. Reacting aminophylline with acids leads to breakdown, forming insoluble theophylline—trouble for anyone hoping for IV clarity. Pharmacy technicians grow familiar with incompatibility hazards, especially with drugs like furosemide or certain antibiotics, which form visible precipitates with aminophylline mixtures. While most clinical applications stick to the core compound, occasional experiments combine it with other methylxanthines to explore pharmacologic synergy.
Aminophylline appears under a handful of names, depending on the country and manufacturer. It answers to synonyms like "theophylline ethylenediamine", "Synthetic theophylline complex", and "diaminomethyl theophylline". Drug stores and hospitals know it through brands such as Phyllocontin, Somophyllin, Truphylline, and Myophyllin. These labels change across continents, but they pivot around the basic composition and therapeutic intent. Regulatory bodies in the UK, US, and Asia all track these names to ensure clarity and consistent therapeutic safety for global shipments.
Safety with aminophylline sits front and center in every hospital protocol. Too little means poor breath for patients. Too much brings jitters, vomiting, and, worst, cardiac arrhythmia. Therapeutic drug monitoring grew from real-life tragedies, not lab studies. Care teams rely on set dosing for age, kidney function, and other meds the patient already takes. Nurses and pharmacists require ongoing training to spot warning signs—in particular, the old “narrow therapeutic index” mantra applies vigorously. Regulatory rules demand locked storage, restricted access, and batch-level traceability in most countries. Staff receive guidance to handle spills or accidental skin contact, with detailed data sheets backing up every risk assessment routine.
Doctors reach for aminophylline in hospital settings where fast, reliable bronchodilation matters. Asthma flares, neonatal apnea, and old-school intravenous therapies all pull aminophylline from the stockroom. Even in the face of inhaled steroids, some patients simply respond better to IV methylxanthine. Emergency rooms in smaller or resource-constrained hospitals often reload aminophylline where newer therapies cost too much. Veterinary medicine finds uses, too—treating respiratory distress in cats, dogs, and horses. Sports medicine and body contouring clinics—outside mainstream medicine—flirted with aminophylline creams for topical fat loss, although evidence remains sketchy at best.
Academic research into aminophylline hasn’t dried up as newer therapies dominate asthma care. Scientists dig into structure-activity relationships, hoping to engineer more selective derivatives with fewer heart and gastrointestinal effects. Some trials focus on adjusting dosing for digital health platforms, integrating point-of-care blood testing that guides aminophylline dosing with real-time feedback. Animal studies, computational models, and practical human observation all blend into a wide research net, aiming for lower toxicity and improved patient outcomes. Interest also rises in combination therapy: pairing aminophylline with anti-inflammatory agents for dual-action relief in chronic lung disease.
Researchers handle aminophylline with a long view shaped by real-world experience. Toxicity ranks as one of its most discussed qualities—a known hazard that forged careful hospital policies. Acute poisoning brings classic effects: vomiting, heart palpitations, seizures, and confusion, all reported throughout decades of clinical practice. Data from poison control centers paints the risk in real numbers—hundreds of serious hospitalizations every year, especially in children or those with impaired metabolism. Researchers test for safer formulations and extended-release delivery to even out absorption, hoping to dial back the risk of overdose for outpatients. Ongoing scrutiny from FDA and global health authorities keeps new risks in check as use patterns change.
Innovation doesn’t pass aminophylline by. As telehealth expands, blood monitoring becomes easier, which might help reintroduce safer home use. Countries with limited drug budgets turn again to aminophylline, seeking cost-effective solutions as inhaler costs climb. R&D teams experiment with microemulsion delivery, skin patches, and nanotechnology, all aimed at gentler drug delivery and a cleaner side-effect profile. Machine learning now parses hospital databases looking for patient groups where aminophylline still beats costlier bronchodilators. As global respiratory disease trends climb, need for flexible, proven agents sticks around—so aminophylline’s old reputation might just get a modern reboot amidst new digital and pharmaceutical advances.
Anyone who has watched a loved one struggle to breathe understands just how frightening a severe asthma attack can be. Relief for tight chests and wheezing doesn’t always arrive from standard inhalers. When these quick fixes don’t help, aminophylline can enter the scene as an emergency back-up. Doctors turn to this medication most often in emergency rooms or intensive care units, where time means everything.
Aminophylline isn’t a household name, but almost every paramedic and hospital pharmacist keeps it in mind for asthma, bronchitis, or chronic obstructive pulmonary disease (COPD). By relaxing muscles around the airways and decreasing the response to irritants, it lets air flow more freely. The sense of relief that can follow such a treatment is something I’ve seen in friends and family with lung disease—suddenly, conversation comes easier, panic subsides, and coughing fits ease up.
Aminophylline belongs to a group of medications called methylxanthines. They work by blocking certain enzymes and calming down over-excited cells in the lungs. This isn’t exactly a miracle cure—side effects can crop up if the dose isn’t right, including jitteriness, headaches, or irregular heartbeat—but it has stood the test of time as one option among several for tough cases.
A big study published in the American Journal of Respiratory and Critical Care Medicine looked at adding aminophylline for severe asthma. It didn’t work as well as newer treatments for every person, but doctors saw it help where others had failed or as an extra line of defense. Across the world, it remains especially useful where newer medications may not be available or affordable. Some community hospitals still rely on aminophylline when budget or resources limit choices.
Modern medicine has delivered so many ways to help those with breathing problems, from rescue inhalers to steroids. Each of these comes with different strengths and weaknesses. Aminophylline gives doctors another option—especially in those rare moments when a patient simply doesn’t respond to what’s standard.
Personal experience shaped my own respect for this medication. I used to volunteer with patients managing severe breathing disorders. Watching someone suddenly turn from panic to calm because a doctor administered aminophylline made its value clear. The sense of hope in that hospital room was hard to forget.
Aminophylline’s biggest challenge is its narrow safety window. Too little, and it doesn’t help. Too much, and problems start. Doctors rely on blood tests to track levels, aiming to avoid side effects like nausea, shaking, or, rarely, dangerous heart rhythms. Patients with heart issues or certain medication mixes face greater risks, so close monitoring is key.
There’s room for improvement in how aminophylline is used. Training new doctors to recognize when the risks are worth it and when alternative medicines will do better saves lives. Pharmaceutical research keeps searching for ways to deliver similar relief with fewer downsides, but for now, aminophylline remains a solid, sometimes life-saving last resort for tough breathing emergencies.
Aminophylline has earned its reputation as an effective bronchodilator for people struggling with asthma or chronic obstructive pulmonary disease (COPD). The tricky part comes from the way this compound acts on the body. Aminophylline widens airways and eases breathing—relief many have come to depend on. Over the years, I’ve watched folks count on it for support during tough asthma attacks. But this medication rarely works in isolation. The body’s reaction often reflects a blend of individual sensitivity, dosage, age, existing health issues, and what other drugs someone may be taking.
What seems like a sure fix to make breathing easier can also bring some troubling side effects. People using aminophylline often report nausea, vomiting, and diarrhea. I remember one patient saying that throwing up actually felt worse than his shortness of breath, putting his whole treatment plan into question. The stomach seems like the first place aminophylline makes its presence known, but that’s only the beginning.
Tremors, insomnia, and nervousness follow next in line. Medical studies—like the long-term observation work published in the “New England Journal of Medicine”—show that people using aminophylline commonly struggle with feeling keyed up. Some folks describe their hands shaking too much to write or drink coffee. Others find themselves staring at the ceiling all night, wondering if their lungs or their medication is keeping them awake.
I’ve cared for a handful of older adults who developed palpitations shortly after starting aminophylline. Heart rate shifts—sometimes minor, sometimes more alarming—continue to crop up in hospital and outpatient reports. The medication unlocks adrenaline-like effects on the heart and blood vessels. The FDA package insert warns that high doses can trigger irregular heartbeats, pounding pulse, or even more severe cardiac complications, especially if someone has a history of heart trouble or thyroid problems.
As people age, the risk for confusion, dizziness, and even seizures rises with aminophylline. The brain’s sensitivity changes, and so does the way kidneys and liver clear medications. This leads to a build-up of aminophylline in the bloodstream, raising the odds of headaches, restlessness, and fainting spells. Doctors usually run frequent blood tests to catch this early, but sometimes these effects slip through, especially if medical follow-up gets skipped.
Rashes or hives show up, although rarely. That doesn’t mean they should ever be brushed off—those signals can hint at something more severe brewing under the surface, like swelling in the throat or trouble breathing. Mixing aminophylline with certain antibiotics, antidepressants, and seizure medications can spike side effect risk by changing blood levels unexpectedly, a situation I’ve seen play out in real clinics and pharmacies.
Managing side effects starts with education. Patients do better when they know what to watch for and how to report changes quickly to their doctor. Pharmacies and health teams need to keep track of all medications in use, not just aminophylline, to reduce dangerous interactions. Using the lowest effective dose for the shortest time, if possible, reduces risk. Regular blood testing helps catch toxic levels before they cause lasting harm. Honest conversations between patient and care team set the foundation for safer, more successful treatment.
Few moments in clinical medicine feel as urgent as managing a tight, wheezy chest in someone struggling for breath. Aminophylline, a drug that has helped both adults and children deal with asthma and chronic obstructive pulmonary disease (COPD), often enters the scene at exactly such times. From my years working in acute care, memories stick of midnight calls where a patient’s bronchi just wouldn’t open and all the simpler treatments had already fallen short. That’s where aminophylline still carries weight.
Most hospitals give aminophylline by intravenous infusion. This method isn’t just about convenience—it comes down to keeping blood levels steady, avoiding toxic peaks and dangerous dips. Doctors and nurses watch every step, starting with a loading dose to bump bloodstream levels quickly, then following up with a maintenance infusion that keeps the concentration in the therapeutic range. People with regular flare-ups might know the taste of aminophylline tablets, but the IV line dominates during emergencies. Oral versions find use for long-term flair, less so when time is short.
Sitting at the bedside of patients on aminophylline has taught me vigilance. Too little, and the lungs stay tight. Too much, and the drug’s dark side shows up: rapid heart, restless body, nausea—signs you won’t miss. Routine blood draws help keep things safe, and so do frequent checks on liver function, since some folks break down aminophylline slower than others. From the tough case of a frail grandma to a young man bouncing back from a bad attack, it’s clear no two patients react quite the same. Decades of research back up this need for personal dosing.
Aminophylline can interact with lots of other drugs—antibiotics, seizure medicines, even certain foods like charcoal-grilled meat. The challenge sits not just in prescribing, but in keeping an eye out for these quiet interactions before a crisis arrives. As someone following up on patient histories, it pays to learn what they’re taking at home and to talk them through the risks in plain language. For those with viral illnesses or heart problems, the body clears aminophylline even slower, and doses should be trimmed back. Errors often come not from bad intent, but from forgetting the details that make or break a safe experience.
One story lingers—a woman in her fifties, in and out of the hospital with every cold. In her case, careful attention to her lifestyle, other meds, and kidney health kept her out of trouble as we balanced oral aminophylline with her busy routine. Shared decision-making pays off. Healthcare teams who listen to patient questions, check lab values regularly, and adjust based on past response build real trust.
While inhalers and new biologics have taken much of the spotlight, aminophylline holds a role where other approaches stall. Training new staff on its risks and benefits keeps it viable. Nurse educators and pharmacists have stepped up—hands-on workshops, regular in-service training, and clear protocols help young clinicians build confidence. Experts urge clinicians to stick to proven guidelines, avoid outdated shortcuts, and keep patients’ needs at the center.
Key Fact: Aminophylline’s narrow therapeutic window means safety grows from teamwork and continuing education. Real-world experience plus robust research keeps patients breathing easier, day or night.Older doctors remember aminophylline as the go-to medicine for kids wheezing in an ER bed. It’s not the newest bronchodilator on the block, but it lingers in many formularies. People who have watched a child struggle for air know how desperate everyone can get for fast solutions. For families dealing with childhood asthma or severe bronchospasm, relief can't come soon enough.
Asthma rates in children keep climbing. Roughly one in every twelve kids in the U.S. now receives that diagnosis. Many factors—pollution, allergens, family history—make it tough for young lungs. Before inhaled steroids and fancy new beta-agonists, theophylline and its cousin aminophylline helped relax airways and delivered results during emergencies.
No parent wants surprises, especially from medications. Here’s where aminophylline stumbles: the line between an effective dose and a toxic one feels much too narrow. In kids, the liver churns through the drug faster or slower than adults, depending on age, health, and what else is going on. What works for one child proves risky for another. Seizures, abnormal heart rhythms, vomiting—these side effects have kept doctors on edge for years. In busy hospitals, nurses still check blood levels because even small dosing mistakes cause trouble fast.
Top medical societies point out that keeping aminophylline levels in the safe zone gets tricky in children, especially since other drugs or fevers change the way aminophylline gets handled in the body. In families with a history of seizures or arrhythmias, most pediatric specialists prefer safer, easier-to-control medicines.
The Global Initiative for Asthma, along with groups like the American Academy of Pediatrics, keeps aminophylline in the toolbox but moves it to a back shelf. They list inhaled beta-2 agonists like albuterol as front-line fixes. If these don’t work, medicines like corticosteroids come before considering aminophylline. Most experts recommend aminophylline only when nothing else works or when resources run thin, like hospitals without newer inhaled options.
Knowing the risks, most children’s hospitals now turn to aminophylline as a last resort. Even so, in parts of the world where budgets run tight and inhalers are scarce, it stays in use. In those cases, careful blood testing and close monitoring become essential—not just handy.
Asthma care changed with new medications that don’t carry aminophylline’s baggage. Inhaled therapies, tailored to children’s age and ability, offer flexibility and rapid results without risky side effects. They also help families manage flare-ups at home, avoiding trips to the ER. For severe cases, other IV options—like magnesium sulfate—offer better safety profiles.
Trust matters most when someone’s child struggles to breathe. If a doctor suggests aminophylline, parents should ask about other options. Understanding why it’s chosen, how it’s monitored, and what side effects to watch for can help keep kids safe. Open conversation with medical teams and knowing up-to-date guidelines helps families feel confident they’re getting the best care.
Doctors, pediatric nurses, and pharmacists working together ensure aminophylline, if ever needed, gets used wisely. Everyone in healthcare wants every child breathing easy and out of danger.
Aminophylline stands out as a medication used for decades to treat breathing disorders like asthma or COPD flare-ups. Anyone who has watched a loved one struggle to breathe during a tough asthma attack knows how much relief an effective bronchodilator can bring. This drug relaxes muscles in the lungs, opening up airways, so it makes a real difference for people gasping for air.
Using aminophylline demands respect for the drug’s potential to both help and harm. Many years ago, I remember a neighbor describing an episode where her son, just eight at the time, received the wrong dosage in the emergency room. He became agitated, his heart raced, and the whole ordeal led to a longer stay. The lesson never left me: improper dosing is no small matter with this medication. The safe window—the therapeutic range—is narrow, so a little too much or too little makes a big difference.
Some folks who take aminophylline might feel shaky, anxious, or complain of stomach pain. More serious signs, such as irregular heartbeats or seizures, signal real trouble. In the rush of treating an asthma attack, symptoms like nausea, vomiting, or jitteriness sometimes go overlooked, but they often mean the drug level in the blood has tipped too high. I’ve seen how experienced nurses keep a sharp eye out for these small but telling changes.
It’s easy to forget how many medicines—prescription or over-the-counter—cross paths with aminophylline. Antibiotics like ciprofloxacin or even common pain relievers can throw off its level in the body. Over time, I’ve come to see how someone adding a new drug or even quitting tobacco suddenly finds themselves with unexpected side effects. Tobacco smoke speeds up how fast the body removes aminophylline, so quitting or cutting down makes the dose act stronger than expected. Caffeine, in coffee or tea, also boosts side effects.
Regular blood tests bring peace of mind in therapy with aminophylline. These check whether the drug level sits in the right spot—not too high, not too low. There’s really no shortcut on this step. Hospitals follow protocols to check blood every so often, especially when someone starts therapy or their health status changes. Doctors adjust the dose based on these results, which probably explains why patients on aminophylline see the lab tech more often.
Communication closes the safety gap. Patients who mention all the supplements and drugs they take help their healthcare team watch for interactions. Healthcare providers do the heavy lifting on calculations and monitoring, but everyone benefits when the person taking aminophylline speaks up about new symptoms or lifestyle changes.
Anyone prescribed aminophylline should keep a list of all medications and share it at every appointment. Watching for side effects, getting labs drawn on schedule, and staying in touch with doctors lead to the best outcomes. Simple habits like keeping a medication diary come in handy when something doesn’t feel right.
Children, older adults, and folks with liver or heart challenges face higher risks with this drug. They need extra vigilance, and doses often run lower. Sharing this info breaks down barriers, so the medication gives more help than harm. Every person taking aminophylline deserves a care plan built around their story—not just their diagnosis.
| Names | |
| Preferred IUPAC name | 1,3-dimethyl-7H-purine-2,6-dione; ethane-1,2-diamine (2:1) |
| Other names |
Aminophyllin Aminofilin Theophylline ethylenediamine |
| Pronunciation | /əˌmɪn.oʊˈfɪl.iːn/ |
| Identifiers | |
| CAS Number | 317-34-0 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Aminophylline**: ``` CC1=NC=NC2=C1N=CN2.CN(C)C(=O)N ``` |
| Beilstein Reference | 3531469 |
| ChEBI | CHEBI:28689 |
| ChEMBL | CHEMBL1547 |
| ChemSpider | 2156 |
| DrugBank | DB01223 |
| ECHA InfoCard | 100.017.225 |
| EC Number | 208-759-1 |
| Gmelin Reference | 6907 |
| KEGG | D07595 |
| MeSH | D000648 |
| PubChem CID | 2158 |
| RTECS number | BX9275000 |
| UNII | 19M8SF377L |
| UN number | UN3155 |
| Properties | |
| Chemical formula | C16H24N10O4 |
| Molar mass | 420.43 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Soluble |
| log P | -0.02 |
| Acidity (pKa) | 5.0 |
| Basicity (pKb) | pKb = 6.1 |
| Magnetic susceptibility (χ) | -52.8e-6 cm³/mol |
| Refractive index (nD) | 1.470 |
| Dipole moment | 2.88 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 324.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -4815 kJ/mol |
| Pharmacology | |
| ATC code | R03DA05 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GF,OP,PR,SP |
| Signal word | Warning |
| Hazard statements | H302+H332: Harmful if swallowed or if inhaled. |
| Precautionary statements | P101 If medical advice is needed, have product container or label at hand. P102 Keep out of reach of children. P103 Read label before use. |
| Autoignition temperature | 370 °C |
| Lethal dose or concentration | LD50 (oral, rat): 225 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Aminophylline: "230 mg/kg (oral, rat) |
| NIOSH | DN2625000 |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | IV: 5 mg/kg q8–12h |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Theophylline Caffeine Paraxanthine Pentoxifylline |
